CY2017008I2 - Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων - Google Patents

Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων

Info

Publication number
CY2017008I2
CY2017008I2 CY2017008C CY2017008C CY2017008I2 CY 2017008 I2 CY2017008 I2 CY 2017008I2 CY 2017008 C CY2017008 C CY 2017008C CY 2017008 C CY2017008 C CY 2017008C CY 2017008 I2 CY2017008 I2 CY 2017008I2
Authority
CY
Cyprus
Prior art keywords
novel compounds
opioid receptor
receptor modulators
modulators
opioid
Prior art date
Application number
CY2017008C
Other languages
English (en)
Other versions
CY2017008I1 (el
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY2017008I2 publication Critical patent/CY2017008I2/el
Publication of CY2017008I1 publication Critical patent/CY2017008I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
CY2017008C 2004-03-15 2017-03-08 Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων CY2017008I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15
PCT/US2005/008339 WO2005090315A1 (en) 2004-03-15 2005-03-14 Novel compounds as opioid receptor modulators

Publications (2)

Publication Number Publication Date
CY2017008I2 true CY2017008I2 (el) 2017-11-14
CY2017008I1 CY2017008I1 (el) 2017-11-14

Family

ID=34962827

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111100967T CY1111927T1 (el) 2004-03-15 2011-10-10 Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
CY20161101019T CY1118096T1 (el) 2004-03-15 2016-10-12 Ρυθμιστες υποδοχεα οπιοειδους
CY2017008C CY2017008I1 (el) 2004-03-15 2017-03-08 Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20111100967T CY1111927T1 (el) 2004-03-15 2011-10-10 Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
CY20161101019T CY1118096T1 (el) 2004-03-15 2016-10-12 Ρυθμιστες υποδοχεα οπιοειδους

Country Status (36)

Country Link
US (8) US7741356B2 (el)
EP (5) EP3112352B1 (el)
JP (1) JP4778954B2 (el)
KR (1) KR101166342B1 (el)
CN (2) CN1950342B (el)
AR (2) AR048269A1 (el)
AT (1) ATE516274T1 (el)
AU (1) AU2005224091B2 (el)
BR (1) BRPI0508820B8 (el)
CA (1) CA2560047C (el)
CR (1) CR8655A (el)
CY (3) CY1111927T1 (el)
DK (5) DK2653465T3 (el)
EC (1) ECSP066856A (el)
ES (5) ES2596434T3 (el)
HK (4) HK1099016A1 (el)
HR (4) HRP20110694T1 (el)
HU (2) HUE029852T2 (el)
IL (3) IL178040A (el)
LT (2) LT2653465T (el)
LU (1) LUC00007I2 (el)
ME (3) ME02221B (el)
MX (1) MXPA06010642A (el)
MY (1) MY146972A (el)
NL (1) NL300865I2 (el)
NO (3) NO338203B1 (el)
NZ (1) NZ549842A (el)
PH (1) PH12012501640A1 (el)
PL (4) PL1725537T3 (el)
PT (4) PT2573068E (el)
RS (4) RS55122B1 (el)
SI (4) SI2653465T1 (el)
TW (1) TWI361069B (el)
UA (1) UA86053C2 (el)
WO (1) WO2005090315A1 (el)
ZA (1) ZA200608587B (el)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
SI2653465T1 (sl) 2004-03-15 2016-10-28 Janssen Pharmaceutica N.V. Modulatorji opiodnih receptorjev
US7244866B2 (en) 2004-05-14 2007-07-17 Janssen Pharmaceutical N.V. Carboxamido opioid compounds
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
ES2535048T3 (es) * 2005-03-14 2015-05-04 Janssen Pharmaceutica Nv Proceso para la preparación de moduladores de opioides
AU2006325754B2 (en) 2005-12-14 2012-04-12 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
SG170767A1 (en) * 2005-12-23 2011-05-30 Zealand Pharma As Modified lysine-mimetic compounds
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2468724T3 (pl) * 2006-12-21 2016-05-31 Zealand Pharma As Synteza związków pirolidynowych
WO2009009480A2 (en) 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
JP2014530244A (ja) 2011-10-13 2014-11-17 エアピオ セラピューティックス， インコーポレイテッド 血管漏出症候群および癌を治療する方法
WO2014153172A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9675587B2 (en) * 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
BR112015022785A2 (pt) 2013-03-14 2017-07-18 Epizyme Inc composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
US10702498B2 (en) 2015-07-09 2020-07-07 The Regents Of The University Of California MU opioid receptor modulators
EP3325450A1 (en) * 2015-07-23 2018-05-30 Teva Pharmaceuticals International GmbH Solid state forms of eluxadoline
CN108026032B (zh) * 2015-09-11 2020-09-29 株式会社钟化 光学活性4-氨基甲酰基-2,6-二甲基苯基丙氨酸衍生物的制造方法
AU2016326510B2 (en) 2015-09-23 2022-03-10 EyePoint Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of Tie-2
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
CN107129444B (zh) * 2016-02-29 2018-08-31 尚科生物医药（上海）有限公司 (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
WO2017191650A1 (en) * 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
EP3463333A4 (en) * 2016-05-30 2019-11-20 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF ELUXADOLINE
WO2017221213A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
US10479769B2 (en) 2016-09-20 2019-11-19 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
EP3573958A1 (en) 2017-01-27 2019-12-04 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
JP6989864B2 (ja) 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
CA3109557A1 (en) 2018-08-20 2020-02-27 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
DK3659433T3 (da) * 2018-11-30 2021-04-19 Phytobiotics Futterzusatzstoffe Gmbh System til analyse af billeder af dyrs afføring
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
AU2020264969A1 (en) 2019-04-29 2021-12-09 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021198780A1 (en) 2020-03-30 2021-10-07 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
AU2021318923A1 (en) * 2020-07-28 2023-03-09 Jazz Pharmaceuticals Ireland Limited Chiral synthesis of fused bicyclic Raf inhibitors
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
US11896728B2 (en) 2020-09-29 2024-02-13 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
HUP9702388A3 (en) * 1995-01-27 1999-01-28 Novo Nordisk As Compounds with growth hormone releasing properties and pharmaceuticals contg. them
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
DE69633442T2 (de) 1995-04-13 2006-01-05 Aventis Pharmaceuticals Inc. Neue substituierte piperazinderivate mit tachykininrezeptor-antagonistischer wirkung
AU6772996A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
WO1997019908A1 (en) 1995-11-29 1997-06-05 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
DK1055665T3 (da) * 1999-05-28 2004-03-01 Pfizer Prod Inc 3-(3-hydroxyphenyl)-3-aminopropionamidderivater
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
DK1392291T3 (da) 2000-10-30 2007-10-08 Janssen Pharmaceutica Nv Tripeptidylpeptidaseinhibitorer
MXPA04003479A (es) * 2001-10-15 2004-07-30 Janssen Pharmaceutica Nv Novedosos derivados de 4-fenil-4[1h-imidazol-2-il]piperidina sustituida y su uso como agonistas selectivos no peptidicos de opiodes delta.
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
SI2653465T1 (sl) 2004-03-15 2016-10-28 Janssen Pharmaceutica N.V. Modulatorji opiodnih receptorjev
JP5070042B2 (ja) 2004-05-03 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物
ES2535048T3 (es) * 2005-03-14 2015-05-04 Janssen Pharmaceutica Nv Proceso para la preparación de moduladores de opioides

Also Published As

Publication number Publication date
ES2533176T3 (es) 2015-04-08
ES2367576T3 (es) 2011-11-04
HK1184432A1 (en) 2014-01-24
EP2298744B1 (en) 2013-06-26
HK1105967A1 (en) 2008-02-29
US8772325B2 (en) 2014-07-08
AU2005224091A1 (en) 2005-09-29
DK3112352T3 (en) 2019-01-28
CA2560047C (en) 2013-12-24
US9700542B2 (en) 2017-07-11
CN102786476A (zh) 2012-11-21
IL229444A0 (en) 2013-12-31
HRP20130800T1 (en) 2013-09-30
PT2298744E (pt) 2013-09-12
LTPA2017005I1 (lt) 2017-03-27
US20050203143A1 (en) 2005-09-15
ME02540B (me) 2017-02-20
PT2653465T (pt) 2016-09-22
ME02221B (me) 2016-02-20
EP3112352B1 (en) 2018-11-21
US8344011B2 (en) 2013-01-01
ES2596434T3 (es) 2017-01-09
EP1725537A1 (en) 2006-11-29
TW200539876A (en) 2005-12-16
KR101166342B1 (ko) 2012-07-18
EP2573068B9 (en) 2015-08-26
US20130090478A1 (en) 2013-04-11
RS54199B1 (en) 2015-12-31
CY1118096T1 (el) 2017-06-28
RS55122B1 (sr) 2016-12-30
AR048269A1 (es) 2006-04-12
HRP20161331T1 (hr) 2016-12-30
BRPI0508820B1 (pt) 2018-04-10
US20180325870A1 (en) 2018-11-15
US8609709B2 (en) 2013-12-17
EP2573068B1 (en) 2014-12-31
US7786158B2 (en) 2010-08-31
JP4778954B2 (ja) 2011-09-21
NO20064660L (no) 2006-12-14
US7741356B2 (en) 2010-06-22
NO338203B1 (no) 2016-08-08
CN102786476B (zh) 2017-01-18
CA2560047A1 (en) 2005-09-29
NO2017007I1 (no) 2017-02-23
PL2298744T3 (pl) 2013-11-29
ATE516274T1 (de) 2011-07-15
PL2573068T3 (pl) 2015-06-30
PH12012501640B1 (en) 2015-10-05
US10213415B2 (en) 2019-02-26
MXPA06010642A (es) 2007-03-26
HUS1700010I1 (hu) 2017-03-28
SI1725537T1 (sl) 2011-11-30
US20080096888A1 (en) 2008-04-24
EP2573068A1 (en) 2013-03-27
DK2298744T3 (da) 2013-09-02
KR20060131983A (ko) 2006-12-20
US20140256779A1 (en) 2014-09-11
HRP20150305T1 (hr) 2015-04-24
PH12012501640A1 (en) 2015-10-05
CR8655A (es) 2008-09-09
UA86053C2 (ru) 2009-03-25
PL1725537T3 (pl) 2011-12-30
BRPI0508820A (pt) 2007-08-07
AR095848A2 (es) 2015-11-18
SI2573068T1 (sl) 2015-03-31
US20160030393A1 (en) 2016-02-04
SI2298744T1 (sl) 2013-10-30
LT2653465T (lt) 2016-09-12
HUE029852T2 (en) 2017-04-28
WO2005090315A1 (en) 2005-09-29
CY2017008I1 (el) 2017-11-14
US20100324051A1 (en) 2010-12-23
DK2653465T3 (da) 2016-08-22
EP2653465A1 (en) 2013-10-23
NL300865I2 (nl) 2020-08-17
LUC00007I2 (el) 2017-05-02
ZA200608587B (en) 2008-06-25
BRPI0508820B8 (pt) 2022-11-29
US20140039024A1 (en) 2014-02-06
NO2017007I2 (no) 2017-02-23
NZ549842A (en) 2010-10-29
US9205076B2 (en) 2015-12-08
MY146972A (en) 2012-10-15
HK1099016A1 (en) 2007-08-03
CN1950342B (zh) 2012-09-26
NO20160916A1 (no) 2006-12-14
DK2573068T3 (en) 2015-02-16
RS52933B (en) 2014-02-28
EP2653465B1 (en) 2016-07-13
EP1725537B1 (en) 2011-07-13
TWI361069B (en) 2012-04-01
SI2653465T1 (sl) 2016-10-28
IL178040A (en) 2013-12-31
ECSP066856A (es) 2006-11-24
EP2298744A3 (en) 2011-08-10
EP3112352A1 (en) 2017-01-04
IL178040A0 (en) 2006-12-31
CN1950342A (zh) 2007-04-18
CY1111927T1 (el) 2015-11-04
HK1155726A1 (en) 2012-05-25
ME01601B (me) 2014-09-20
ES2428008T3 (es) 2013-11-05
DK1725537T3 (da) 2011-10-31
PT1725537E (pt) 2011-09-08
LUC00007I1 (el) 2017-03-03
IL229444A (en) 2017-03-30
PT2573068E (pt) 2015-04-27
PL2653465T3 (pl) 2017-01-31
LTC1725537I2 (lt) 2018-02-26
AU2005224091B2 (en) 2012-02-02
ES2705077T3 (es) 2019-03-21
HRP20110694T1 (hr) 2011-12-31
IL224908A (en) 2015-07-30
EP2298744A2 (en) 2011-03-23
NL300865I1 (nl) 2017-03-14
JP2007529527A (ja) 2007-10-25
RS51995B (en) 2012-04-30

Similar Documents

Publication Publication Date Title
CY2017008I2 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
ATE490251T1 (de) Tricyclische opioidmodulatoren
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
EP1906962A4 (en) OCTAHYDROISOCHINOLIN COMPOUNDS AS OPIOID RECEPTOR MODULATORS
ITMI20042238A1 (it) Composti per fluoropolirterei
ATE384719T1 (de) Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen
SE0402103D0 (sv) Novel compounds
SE0400022D0 (sv) New compounds
SE0400254D0 (sv) New compounds
SE0403054D0 (sv) Novel compounds
SE0402069D0 (sv) Novel compounds
SE0401348D0 (sv) Novel compounds
SE0402068D0 (sv) Novel compounds
SE0400286D0 (sv) Novel Compounds
SE0401885D0 (sv) Novel compounds
DOP2004000959A (es) Compuestos
SE0402391D0 (sv) Novelheterocyclic compounds
TH105710B (th) โอพิออยด์รีเซปเตอร์แอนตะกอนิสต์
SE0401324D0 (sv) New compounds
SE0401658D0 (sv) New compounds
SE0401332D0 (sv) New compounds
SE0400227D0 (sv) New compounds
SE0400102D0 (sv) New compounds
SE0400044D0 (sv) New compounds
SE0401344D0 (sv) New compounds